NanoMosaic and Solid Biosciences announced a comarketing agreement aimed at improving genetic drug delivery and manufacturing analytics for AAV gene therapies. The collaboration pairs NanoMosaic’s Tessie automated plate reader—built to multiplex measure vector genomes and capsid titers—with Solid Biosciences’ Polaris-101 capsid targeting skeletal muscle and cardiac tissue. The Tessie platform is positioned to quantify full, partial, and empty capsids alongside transgene measurements, targeting an area that impacts dosing accuracy and safety. NanoMosaic previously received FDA Advanced Manufacturing Technology (AMT) designation for Tessie, underscoring the system’s alignment with regulatory expectations. For developers, the product pairing is designed to support safer and more consistent dosing and to streamline decision-making in vector production and assessment workflows. The agreement also reflects continued industry focus on translating manufacturing innovations into commercial-scale quality control—an operational priority as more AAV-based therapies move through late-stage development and into broader clinical use.